AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34959133 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker concentration (S100B)
Number of subjects: 2869
Study 34959133 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised k-means biomarker clustering
Number of subjects: 2869
Study 34959641 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSP9v3
Number of subjects: 8
Study 34959855 — intervention group
Group type: EXPERIMENTAL
Intervention: Household food insecurity (HFI)
Number of subjects: 672
Study 34959982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D supplementation (100,000 IU 25-OH VD every 3 weeks from day 1 of cycle 1 to day 1 of cycle 5)
Number of subjects: 44
Study 34959982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D supplementation
Number of subjects: 44
Study 34961326 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% O2 exposure
Number of subjects: 0
Study 34961326 — intervention group
Group type: COMPARATOR
Intervention: Room air (controls)
Number of subjects: 0
Study 34961326 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 34961476 — intervention group
Group type: EXPERIMENTAL
Intervention: High hs-CRP levels (> 3 mg/L)
Number of subjects: 1449
Study 34961476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia
Number of subjects: 1449
Study 34961476 — intervention group
Group type: EXPERIMENTAL
Intervention: High hs-CRP levels (> 3 mg/L) and hypoalbuminemia
Number of subjects: 1449
Study 34961518 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health Programme for Young Children (PLH-YC, 5 sessions)
Number of subjects: 864
Study 34961518 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture on parenting issues (control group, 1 session)
Number of subjects: 864
Study 34961547 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg daily for 14 weeks)
Number of subjects: 40
Study 34961547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34961558 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Pancreatoduodenectomy (RPD)
Number of subjects: 244
Study 34961558 — intervention group
Group type: COMPARATOR
Intervention: Open Pancreatoduodenectomy (OPD)
Number of subjects: 244
Study 34961558 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Pancreatoduodenectomy (RPD) in a sub-cohort of 128 patients with pancreatic adenocarcinoma (PDAC)
Number of subjects: 244
Study 34961558 — intervention group
Group type: COMPARATOR
Intervention: Open Pancreatoduodenectomy (OPD) in a sub-cohort of 128 patients with pancreatic adenocarcinoma (PDAC)
Number of subjects: 244
Study 34961567 — intervention group
Group type: EXPERIMENTAL
Intervention: CombinADO strategy (intervention) including peer support, informational/motivational video, support groups for AYAHIV caregivers, AYAHIV support groups, and mental health screening and linkage to adolescent-focused mental health support.
Number of subjects: 0
Study 34961567 — intervention group
Group type: COMPARATOR
Intervention: Optimized standard of care (control) including billboards/posters, radio shows, healthcare worker training, one-stop adolescent and youth-friendly services, information/motivation walls, pill containers, and tools for HCW during clinical visits.
Number of subjects: 0
Study 34961567 — intervention group
Group type: EXPERIMENTAL
Intervention: CombinADO strategy (intervention)
Number of subjects: 0
Study 34961567 — intervention group
Group type: COMPARATOR
Intervention: Optimized standard of care (control)
Number of subjects: 0
Study 34961659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated radiotherapy (5 to 7 fractions)
Number of subjects: 0
Study 34961659 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy or stereotactic body radiotherapy
Number of subjects: 0
Study 34961659 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction high dose rate brachytherapy
Number of subjects: 0
Study 34961902 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood total mtDNA variant number above the median value for the study cohort, coexisting with an mtDNA non-H haplogroup
Number of subjects: 44
Study 34961902 — intervention group
Group type: EXPERIMENTAL
Intervention: Abundant mtDNA variants
Number of subjects: 44
Study 34961902 — intervention group
Group type: EXPERIMENTAL
Intervention: High relative levels of circulating tumour-targeting effector T cells
Number of subjects: 44
Study 34961902 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerous mtDNA polymorphisms in peripheral blood
Number of subjects: 44
Study 34961902 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's constitutional mtDNA
Number of subjects: 44
Study 34961921 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH-aided radioiodine treatment
Number of subjects: 321
Study 34961921 — intervention group
Group type: COMPARATOR
Intervention: radioiodine alone
Number of subjects: 321
Study 34962134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon-based PVI
Number of subjects: 17356
Study 34962177 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous telemedicine assessments
Number of subjects: 127
Study 34962177 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed controls
Number of subjects: 127
Study 34962628 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment for T2DM
Number of subjects: 1798
Study 34962901 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural sedation conducted by nonphysician providers
Number of subjects: 336
Study 34962901 — intervention group
Group type: COMPARATOR
Intervention: Procedural sedation conducted by physician providers
Number of subjects: 336
Study 34963453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led face-to-face intervention (FOCUS+)
Number of subjects: 936
Study 34963453 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (iFOCUS)
Number of subjects: 936
Study 34963453 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 936
Study 34963493 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesiologist-assisted ultrasound-guided erector spinae catheter
Number of subjects: 80
Study 34963493 — intervention group
Group type: COMPARATOR
Intervention: Surgeon-assisted video-assisted paravertebral catheter
Number of subjects: 80
Study 34963501 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 82
Study 34963501 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 82
Study 34963501 — intervention group
Group type: EXPERIMENTAL
Intervention: combined group analysis (tDCS + robotic therapy)
Number of subjects: 82
Study 34963501 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive robotic therapy
Number of subjects: 82
Study 34963501 — intervention group
Group type: EXPERIMENTAL
Intervention: combined intervention (tDCS + robotic therapy)
Number of subjects: 82
Study 34963501 — intervention group
Group type: EXPERIMENTAL
Intervention: wrist submovement characteristics
Number of subjects: 82
Study 34963502 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy and transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 34963563 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Number of subjects: 156
Study 34963563 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 156
Study 34963655 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ASD screening and evaluation process
Number of subjects: 26
Study 34963655 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal ASD screening
Number of subjects: 26
Study 34963655 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive ASD screen
Number of subjects: 26
Study 34964367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) using a novel PFA system (PulseSelect; Medtronic, Inc)
Number of subjects: 38
Study 34964367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 38
Study 34964890 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 7573
Study 34964890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7573
Study 34964932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone treatment (Cohort 1)
Number of subjects: 30
Study 34964932 — intervention group
Group type: COMPARATOR
Intervention: Control (Cohort 2)
Number of subjects: 30
Study 34964996 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaPrint
Number of subjects: 121
Study 34964996 — intervention group
Group type: EXPERIMENTAL
Intervention: BluePrint
Number of subjects: 121
Study 34965032 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination
Number of subjects: 49
Study 34965620 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic periodontitis and type 2 diabetes
Number of subjects: 40
Study 34965620 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 40
Study 34965883 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 119
Study 34965883 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgens for long-term prophylaxis
Number of subjects: 119
Study 34965890 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor with carboplatin, doxorubicin, and cyclophosphamide (DC)
Number of subjects: 19
Study 34965890 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor with irinotecan, fluorouracil, and folinic acid (FOLFIRI)
Number of subjects: 19
Study 34965890 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor with irinotecan, capecitabine, and oxaliplatin (XELOX)
Number of subjects: 19
Study 34965890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral selinexor with different standard chemotherapies
Number of subjects: 19
Study 34965951 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in STS cohort
Number of subjects: 40
Study 34965951 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in ovarian carcinoma cohort
Number of subjects: 40
Study 34966107 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlifidase-generated single-cleaved IgG (scIgG)
Number of subjects: 0
Study 34966107 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated scIgG from a highly HLA-sensitized individual
Number of subjects: 0
Study 34966107 — intervention group
Group type: EXPERIMENTAL
Intervention: Imlifidase treatment
Number of subjects: 0
Study 34966186 — intervention group
Group type: EXPERIMENTAL
Intervention: Water supplementation
Number of subjects: 31
Study 34966256 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors of clinical progression in early PD
Number of subjects: 0
Study 34966299 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34966645 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive score using noncontrast-enhanced MRI (CHESS-DIS score)
Number of subjects: 149
Study 34966667 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity program during neoadjuvant chemotherapy (NACT) combining aerobic and strengthening exercises.
Number of subjects: 70
Study 34966795 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34966798 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 34966798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 34966798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 34966798 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard treatment not specified)
Number of subjects: 0
Study 34966799 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical Assessment
Number of subjects: 0
Study 34966799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pullback Resting full-cycle ratio (RFR) Measurement
Number of subjects: 0
Study 34966951 — intervention group
Group type: EXPERIMENTAL
Intervention: End-expiratory lung volume measured with volumetric capnography (EELV)
Number of subjects: 0
Study 34966951 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34966981 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders group (N = 103)
Number of subjects: 409
Study 34966981 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD group (N = 118)
Number of subjects: 409
Study 34966981 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N = 28)
Number of subjects: 409
Study 34966981 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent participants (ages 13-17 years) in anxiety disorders group
Number of subjects: 409
Study 34967448 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of the primary canine
Number of subjects: 199
Study 34967448 — intervention group
Group type: COMPARATOR
Intervention: No extraction (control)
Number of subjects: 199
Study 34967448 — intervention group
Group type: EXPERIMENTAL
Intervention: Double primary tooth extraction
Number of subjects: 199
Study 34967448 — intervention group
Group type: COMPARATOR
Intervention: Single primary tooth extraction
Number of subjects: 199
Study 34967504 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day ART (SDART)
Number of subjects: 1904
Study 34967751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based cognitive battery (Adaptive Cognitive Evaluation [ACE])
Number of subjects: 53
Study 34967751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based cognitive battery (ACE)
Number of subjects: 53
Study 34967755 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS (Motivation And Problem Solving)
Number of subjects: 202
Study 34967755 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 202
Study 34967894 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified rice extruded with citric acid (CA) and trisodium citrate (TSC)
Number of subjects: 22
Study 34967894 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified rice extruded without CA/TSC
Number of subjects: 22
Study 34967916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg Q2W from Week 12 to Week 20
Number of subjects: 12
Study 34968102 — intervention group
Group type: EXPERIMENTAL
Intervention: General cognitive training (two interventions)
Number of subjects: 0
Study 34968102 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific instrumental activities of daily living (IADL) training (one intervention)
Number of subjects: 0
Study 34968102 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 34968106 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline (1 mg/bid)
Number of subjects: 115
Study 34968106 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline (1 mg/bid) plus naltrexone (50 mg/day)
Number of subjects: 115
Study 34968756 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 1459
Study 34968756 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2 mg
Number of subjects: 1459
Study 34969046 — intervention group
Group type: EXPERIMENTAL
Intervention: I-Score intervention via smartphone application (Opal)
Number of subjects: 32
Study 34969173 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT-HF risk factors (hypertension, stable angina, unstable angina, myocardial infarction, diabetes)
Number of subjects: 170885
Study 34969173 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT-CVD risk factors (smoking, obesity)
Number of subjects: 170885
Study 34969173 — intervention group
Group type: COMPARATOR
Intervention: No RCT-HF RFs
Number of subjects: 170885
Study 34969173 — intervention group
Group type: COMPARATOR
Intervention: No RCT-CVD RFs
Number of subjects: 170885
Study 34969173 — intervention group
Group type: COMPARATOR
Intervention: No RF or only RCT-0 RFs
Number of subjects: 170885
Study 34969254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring designs (four designs presented via a visual tool)
Number of subjects: 0
Study 34969397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 111
Study 34969397 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR myocarditis
Number of subjects: 111
Study 34969397 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge status
Number of subjects: 111
Study 34969408 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized questionnaire measuring sedentary time
Number of subjects: 131
Study 34969408 — intervention group
Group type: EXPERIMENTAL
Intervention: Original and optimized questionnaires
Number of subjects: 131
Study 34969408 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized questionnaire
Number of subjects: 131
Study 34969408 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed questionnaire
Number of subjects: 131
Study 34969496 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated speech analysis technology (HearO)
Number of subjects: 40
Study 34969647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary palliative care approach (physiotherapist, psychologist, pulmonologists, palliative care doctors)
Number of subjects: 50
Study 34969647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary palliative care approach
Number of subjects: 50
Study 34969647 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 34969664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for insomnia (CBT-I), 5 sessions, gold-standard treatment.
Number of subjects: 20
Study 34969664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy for insomnia (CBT-I)
Number of subjects: 20
Study 34969665 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo naturalis (IN) 500 mg/day or 1.5 g/day for 8 weeks
Number of subjects: 11
Study 34970227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) group
Number of subjects: 5154
Study 34970227 — intervention group
Group type: COMPARATOR
Intervention: Non-Diabetes Mellitus (non-DM) group
Number of subjects: 5154
Study 34970476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 0
Study 34970476 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 34970487 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab plus nivolumab
Number of subjects: 10
Study 34970487 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab
Number of subjects: 10
Study 34970487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 10
Study 34970487 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 10
Study 34970731 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 2257
Study 34970731 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 2257
Study 34970731 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 2257
Study 34970731 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 2257
Study 34970731 — intervention group
Group type: COMPARATOR
Intervention: Pooled placebo
Number of subjects: 2257
Study 34970744 — intervention group
Group type: EXPERIMENTAL
Intervention: Free epithelialized gingival/mucosal grafts (FEGs) used for KT augmentation
Number of subjects: 52
Study 34970774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole therapy
Number of subjects: 59
Study 34970774 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of serum C-reactive protein and albumin levels
Number of subjects: 59
Study 34970860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 0
Study 34970860 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34971075 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 37
Study 34971362 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated men (HYPER2)
Number of subjects: 327
Study 34971362 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated men (HYPER1)
Number of subjects: 327
Study 34971582 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (aged ≥15 years)
Number of subjects: 1907
Study 34971582 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (aged <15 years)
Number of subjects: 1907
Study 34971582 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with non-mixed cellularity histology
Number of subjects: 1907
Study 34971582 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with mixed cellularity
Number of subjects: 1907
Study 34971582 — intervention group
Group type: COMPARATOR
Intervention: Younger patients with mixed cellularity
Number of subjects: 1907
Study 34971582 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 1907
Study 34971971 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Zol) in conjunction with radiation therapy (RT)
Number of subjects: 0
Study 34971971 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Zol) + RT
Number of subjects: 0
Study 34971971 — intervention group
Group type: COMPARATOR
Intervention: FDPS overexpression in PDAC tissues and cells
Number of subjects: 0
Study 34972140 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapeutic intervention targeting midline frontal theta (MFT) circuitry for 4 weeks on an iPad
Number of subjects: 25
Study 34972140 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapeutic intervention targeting midline frontal theta (MFT) circuitry
Number of subjects: 25
Study 34972202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus dinaciclib
Number of subjects: 72
Study 34972234 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy siblings of children with rare congenital surgical diseases
Number of subjects: 81
Study 34972260 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25mcg
Number of subjects: 0
Study 34972260 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25mcg
Number of subjects: 0
Study 34972260 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25mcg
Number of subjects: 0